Japan's SoftBank is reportedly close to becoming the biggest investor in generative artificial intelligence leader OpenAI, ...
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback